Top

20-04-2024 | Alopecia | Short Communication

Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia

Authors: Takumi Tsuji, Katsuaki Yoneda, Yu Igawa, Erika Minamino, Nodoka Otani, Yuya Yoshida, Takeyuki Kohno

Published in: Cancer Chemotherapy and Pharmacology

Abstract

Purpose

We investigated the inhibitory effect of edaravone (EDR) lotion on chemotherapy-induced alopecia (CIA) to improve the quality of life for patients with cancer.

Methods

Wistar rats were intraperitoneally injected with cyclophosphamide (CPA, 75 mg/kg) to induce CIA and divided into six groups: (1) Control; (2) EDR 0%; (3) EDR 0.3%; (4) EDR 3%. The TUNEL-positive area was examined histologically, and mRNA expression levels of the apoptosis-related factors, such as B-cell/CLL lymphoma 2 (Bcl-2), and Bcl-2-associated X protein (Bax), were determined.

Results

In the three CPA-treated groups, a decrease in the coverage score (percentage of hairs covered) was observed from days 16 to 18. In addition, coverage scores on day 21, the last day of observation, showed a tendency for the suppression of hair loss to increase, though hair loss was observed in all groups. The coverage scores of the EDR 0.3% and 3% groups after day 17 were significantly higher than those of the EDR 0% group. The TUNEL-positive area of skin tissue on day 16 was extensive in the EDR 0% group and decreased in the EDR 0.3% and 3% groups. The mRNA expression ratio of Bcl-2/Bax on day 21 was maintained at the same level as that of the control group only in the EDR 3% group.

Conclusion

This study confirmed the use of EDR lotion to inhibit hair loss, indicating that the clinical application of EDR lotion may improve the quality of life for patients with cancer and their willingness to undergo treatment.

Available only for authorised users

Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17:317–328. https://doi.org/10.1002/pon.1245CrossRefPubMed

Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D (2004) Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 12:543–549. https://doi.org/10.1007/s00520-003-0562-5CrossRefPubMed

McGarvey EL, Baum LD, Pinkerton RC, Rogers LM (2001) Psychological sequelae and alopecia among women with cancer. Cancer Pract 9:283–289. https://doi.org/10.1111/j.1523-5394.2001.96007.pp.xCrossRefPubMed

Fisher B, Brown AM, Dimitrov V, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical adjuvant breast and Bowel Project B-15. J Clin Oncol 8:1483–1496. https://doi.org/10.1200/JCO.1990.8.9.1483CrossRefPubMed

Martín M, Rodríguez-Lescure Á, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitán MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Marco JMG, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí, Mel JR, Aranda E, Adrover E, Álvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, On behalf of the GEICAM 9906 Study Investigators (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805–814. https://doi.org/10.1093/jnci/djn151CrossRefPubMed

Watanabe T, Yagata H, Saito M, Okada H, Yajima T, Tamai N, Yoshida Y, Takayama T, Imai H, Nozawa K, Sangai T, Yoshimura A, Hasegawa Y, Yamaguchi T, Shimozuma K, Ohashi Y (2019) A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLoS ONE 14:e0208118. https://doi.org/10.1371/journal.pone.0208118CrossRefPubMedPubMedCentral

Brien RO, Zelson JH, Schwartz AD, Pearson HA (1970) Scalp tourniquet to lessen alopecia after vincristine. N Engl J Med 283:1469. https://doi.org/10.1056/nejm197012242832621CrossRef

Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S, Holmes F, Abraham J, Lacouture M, Courtright J, Paxman R, Rude M, Hilsenbeck S, Osborne CK, Rimawi M (2016) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 317:596–605. https://doi.org/10.1001/jama.2016.20939CrossRef

FDA NEWS RELEASE (2017) FDA clears expanded use of cooling cap to reduce hair loss during chemotherapy. https://www.fda.gov/news-events/press-announcements/fda-clears-expanded-use-cooling-cap-reduce-hair-loss-during-chemotherapy

10.

de Barros Silva G, Ciccolini K, Donati A, van den Hurk C (2020) Scalp cooling to prevent chemotherapy-induced alopecia. Bras Dermatol 95:631–637. https://doi.org/10.1016/j.abd.2020.03.005CrossRef

11.

Komen MMC, Smorenburg CH, Hurk CJG, Nortier JWR (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18:885–891. https://doi.org/10.1634/theoncologist.2012-0332CrossRefPubMedPubMedCentral

12.

Kanchanlata S, Mustansir B, Yasar AK, Ganapathi B, Thankamani M (2018) Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity - exploring the armoury of obscurity. Saudi Pharm J 26:177–190. https://doi.org/10.1016/j.jsps.2017.12.013CrossRef

13.

Simone IICB, Simone NL, Simone V, Simone CB (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 13:22–28PubMed

14.

15.

Hendrix S, Handjiski B, Peters MJ, Paus R (2005) A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice. J Invest Dermatol 125:42–51. https://doi.org/10.1111/j.0022-202X.2005.23787.xCrossRefPubMed

16.

Yoneda K, Fujii M, Imaoka A, Kobayashi R, Hayashi R, Yoshida Y, Kohno T, Tsuji T (2021) Preventive effect of edaravone ointment on cyclophosphamide-chemotherapy induced alopecia. Support Care Cancer 29:6127–6134. https://doi.org/10.1007/s00520-021-06189-7CrossRefPubMed

17.

Onaolapo AY, Adebayo AA, Onaolapo OJ (2018) Oral phenytoin protects against experimental cyclophosphamide-chemotherapy induced hair loss. Pathophysiology 25:31–39. https://doi.org/10.1016/j.pathophys.2017.12.001CrossRefPubMed

18.

Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, Yang B (2010) Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 159:1584–1594. https://doi.org/10.1111/j.1476-5381.2009.00551.xCrossRefPubMedPubMedCentral

19.

Philpott MP, Sanders DA, Kealey T (1994) Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations is an important regulator of hair follicle growth in vitro. J Invest Dermatol 102:857–861. https://doi.org/10.1111/1523-1747.ep12382494CrossRefPubMed

20.

Soref CM, Fahl WE (2015) A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor. Int J Cancer 136:195–203. https://doi.org/10.1002/ijc.28961CrossRefPubMed

Title: Preventive effect of free radical scavenger edaravone lotion on cyclophosphamide chemotherapy-induced alopecia
Authors: Takumi Tsuji
Katsuaki Yoneda
Yu Igawa
Erika Minamino
Nodoka Otani
Yuya Yoshida
Takeyuki Kohno
Publication date: 20-04-2024
Publisher: Springer Berlin Heidelberg
Keywords: Alopecia
Cytostatic Therapy
Published in: Cancer Chemotherapy and Pharmacology
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-024-04669-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine